Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences
J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences
Read also
Cardiff Oncology's Onvansertib Earns FDA Fast Track for Colorectal Cancer
FDA granted Fast Track designation to Cardiff Oncology's onvansertib combination for RAS-mutated metastatic colorectal cancer after Phase 2 results.
AstraZeneca Wins FDA Approval for Imfinzi-Padcev Combo in Bladder Cancer
FDA approved AstraZeneca's Imfinzi plus Padcev for certain muscle-invasive bladder cancer patients, supported by VOLGA Phase III survival results.
Glenmark Launches Generic Axitinib in US as Cancer Drug Shares Rise 2%
Glenmark launched authorized generic axitinib tablets in the US for kidney cancer, entering a market where INLYTA sales reached $538.4 million in 12 months.
Lilly to Acquire Calytrix Bio for Up to $1.5B in Mutant CALR Antibody Deal
Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, adding a preclinical antibody targeting mutant calreticulin in rare blood disorders.